PharmaCyte Biotech Company Insiders

PharmaCyte Biotech Management Team Effectiveness

The company has return on total asset (ROA) of (0.0476) % which means that it has lost $0.0476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1768) %, meaning that it created substantial loss on money invested by shareholders. PharmaCyte Biotech's management efficiency ratios could be used to measure how well PharmaCyte Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At present, PharmaCyte Biotech's Return On Tangible Assets are projected to slightly grow based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.58, whereas Return On Capital Employed is forecasted to decline to (0.09). At present, PharmaCyte Biotech's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 34.4 M, whereas Total Current Assets are forecasted to decline to about 13 M. As of December 29, 2025, Common Stock Shares Outstanding is expected to decline to about 7 M. In addition to that, Net Loss is expected to decline to about (5.1 M)

PharmaCyte Biotech Workforce Comparison

PharmaCyte Biotech Insider Trading

PharmaCyte Biotech Notable Stakeholders

The success or failure of an entity such as PharmaCyte Biotech often depends on how effective the management is. PharmaCyte Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of PharmaCyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the PharmaCyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of PharmaCyte Biotech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PharmaCyte Biotech's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of PharmaCyte Biotech's management manipulating its earnings.

When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.